Related Experiment Videos
NN-2211 Novo Nordisk
1Boehringer Ingelheim Pharma GmbH & Co KG, Department of Metabolic Research, Birkendorfer Strasse 65 88397, Biberach an der Riss, Germany. michael.mark@bc.boehringer-ingelheim.com
Idrugs : the Investigational Drugs Journal
|June 6, 2003
Abstract:
Novo Nordisk A/S, under license from Scios Inc, is developing NN-2211, a stable analog of the naturally occurring peptide hormone glucagon-like peptide 1 (GLP-1), which stimulates insulin release in response to increases in blood sugar levels, for the potential treatment of type 2 diabetes.